Teva Pharmaceutical Industries Ltd saw a price increase of 3.01%, reaching a 52-week high as the company submitted a New Drug Application for its olanzapine long-acting injectable.
This innovative treatment aims to provide a once-monthly subcutaneous option for adult schizophrenia patients, addressing a significant treatment gap. The submission is based on positive results from the Phase 3 SOLARIS trial, which demonstrated the drug's efficacy and safety over 56 weeks.
The market is optimistic about Teva's potential to improve patient adherence and reduce relapse rates with this new formulation. As a result, investors are closely watching Teva's performance, especially given the recent increase in Glenview Capital Management's stake in the company.
Wall Street analysts forecast TEVA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TEVA is 35.71 USD with a low forecast of 29.00 USD and a high forecast of 40.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Analyst Rating
Wall Street analysts forecast TEVA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TEVA is 35.71 USD with a low forecast of 29.00 USD and a high forecast of 40.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Buy
1 Hold
0 Sell
Strong Buy
Current: 33.210
Low
29.00
Averages
35.71
High
40.00
Current: 33.210
Low
29.00
Averages
35.71
High
40.00
Barclays
Glen Santangelo
Overweight
maintain
$35 -> $38
2026-01-30
New
Reason
Barclays
Glen Santangelo
Price Target
$35 -> $38
AI Analysis
2026-01-30
New
maintain
Overweight
Reason
Barclays analyst Glen Santangelo raised the firm's price target on Teva to $38 from $35 and keeps an Overweight rating on the shares. The firm updated the company's model post the Q4 report and remains confident in the shares at these levels.
Scotiabank
Outperform
maintain
$35 -> $40
2026-01-29
New
Reason
Scotiabank
Price Target
$35 -> $40
2026-01-29
New
maintain
Outperform
Reason
Scotiabank raised the firm's price target on Teva to $40 from $35 and keeps an Outperform rating on the shares. The firm is positive on the stock following Q4 results and increased its price target on the stock due to the company's execution continuing to exceed expectations, the analyst tells investors.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for TEVA
Unlock Now
Truist
Buy
maintain
$32 -> $36
2026-01-07
Reason
Truist
Price Target
$32 -> $36
2026-01-07
maintain
Buy
Reason
Truist raised the firm's price target on Teva to $36 from $32 and keeps a Buy rating on the shares. The affordable medicines theme remains attractive heading into 2026, the analyst tells investors in a research note.
Jefferies
Buy
maintain
$29 -> $40
2026-01-06
Reason
Jefferies
Price Target
$29 -> $40
2026-01-06
maintain
Buy
Reason
Jefferies raised the firm's price target on Teva to $40 from $29 and keeps a Buy rating on the shares, which the analyst introduced as a top 2026 idea. The narrative should shift in 2026 and beyond with several pipeline catalysts, but key is convincing investors to ascribe a positive terminal value to reflect R&D productivity when historically none was given, says the analyst, who expects the R&D engine to "start bearing fruit in 2026."
About TEVA
Teva Pharmaceutical Industries Ltd is a Israeli-based pharmaceutical company. The Company operates through three segments: North America, Europe and International Markets. Each business segment manages entire product portfolio in its region, including generics, specialty and over-the-counter (OTC) products. In addition to these three segments, The Company has other activities, primarily the sale of active pharmaceutical ingredients (API) to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
